CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gordon James who wrote (243)	8/22/1999 12:51:00 PM
From: Biomaven	Read Replies (3) of 666

Welcome to SI! Here's a site that lists a number Bexxar trials, including a Bexxar/Fludarabine for low-grade NHL: lymphoma.org Here's the trial: Fludarabine + Iodine-131 Anti-B1 Antibody (Bexxar) for Untreated Low Grade, Advanced Stage NHL (CP-98-025) December, 1998.This study is for low grade or transformed low grade Non-Hodgkin's lymphoma with stage III or IV of the disease. The following cell types are eligible: small lymphocytic, follicular small-cleaved, follicular mixed, follicular large-cell and monocytoid B-cells. Patients must not have had ANY previous therapy, never received systemic steroids within 1 week of study entry, no HIV or active infections, no brain metastases and no prior non-lymphoma malignancies. Patients will receive 3 cycles of fludarabine, then unlabeled anti-B1 antibody followed by labeled anti-B1 antibody. Antibodies are given intravenously: 2 injections given about a week apart. Hospitalization may be required for several days after the second injection. For more information, please contact Dr. John Leonard, New York University - Cornell Medical Center at (212) 746-2095. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next